Position of EHA on the Harmonization of Training and Education in Europe

Trainees and specialists in hematology must be fit for practice. It is our mission to promote excellence in education in European hematology. To improve patient care and public health it is essential to raise and maintain the skills and competences of hematologists to an equally high standard across European countries. Therefore, we aim to harmonize and improve training and education in hematology in Europe.

Read more

Position of EHA on Research Funding

It’s in the blood of hematologists to do research. It is our mission to promote research in European hematology. To sustain and improve research in blood disorders, it is essential to secure funding. Therefore, we seek to improve funding opportunities for research in blood disorders in Europe.

Read more

Position of EHA on Clinical Trials

It’s in the blood of hematologists to do research. It is our mission to promote research in European hematology. To sustain and improve the discovery (or the verification of the effects) of medicines to treat blood disorders it is essential that the requirements for clinical research add value, especially where investigator-driven research is concerned. Therefore we seek to improve the regulations for the performance of clinical trials of blood disorders in Europe.

Read more

Position of EHA on Personalized Medicine

Personalized medicine is revolutionizing the way blood disorders are managed and researched. It is our mission to promote excellence in research, education, and clinical practice in hematology. To achieve this, it is important to promote personalized medicine. Therefore, we seek to improve the conditions that allow for the support of personalized medicine.

Read more

Targeting the B-cell Receptor in Aggressive B-cell Lymphomas

Stockholm, June 14, 2013 Dr Wyndham Wilson will give an update on recent developments in the treatment of lymphomas with small molecules. The last 30 years have seen a plethora of treatments for diffuse large B-cell lymphoma (DLBCL) but few advances have been made. Recent studies have identified B-cell receptor signaling as critical for many B-cell lymphomas including the most common type, called diffuse large B-cell lymphoma (DLBCL). Recent studies have shown that DLBCL is actually not a single disease but at least 3 different diseases, each with its own critical abnormalities that allow it to survive as a malignancy.  The most difficult to treat type of DLBCL is called the Activated B-cell (ABC) subtype, which is dependent on abnormal signaling of the B-cell receptor (BCR). Work by Dr. Lou Staudt has shown that these tumors will die when this pathway is inhibited.

Read more

Pomalidomide prolongs survival in refractory myeloma patients

Stockholm, June 14, 2013 Dr Jesus San-Miguel will present promising results of a phase 3 study in multiple myeloma.
Treatment for patients with multiple myeloma (MM) has improved over the last decade due to the introduction of new drugs such as lenalidomide and bortezomib. However, after receiving multiple treatments, MM patients often become resistant (refractory) to these drugs and have an average survival of only 9 months.

Read more

Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma – an...

Stockholm, June 14, 2013 Dr Henk Lokhorst will present the results from a phase I/II study in advanced Multiple Myeloma.
Multiple myeloma is the second most common hematological cancer. It is a cancer of plasma cells and it accounts for approx. 1% of all cancers. At present, no cure is available. The 5-year relative survival rate for multiple myeloma is around 40% so there is a strong need for new treatment modalities to improve the survival.

Read more

Mini-hormone fights iron

Stockholm, June 14, 2013 Dr Elizabeta Nemeth will present findings of a study in patients with iron overload disorders that will contribute to the design of a potential new treatment at the 18th Congress of the European Hematology Association in Stockholm.

Read more

TARGETING THE JAK-STAT PATHWAY IN MALIGNANT AND NON-MALIGNANT CELLS IN MYELOPROL...

Stockholm, June 14, 2013 Dr Ross Levine will present the results from a study on targeting the JAK-STAT pathway in myeloproliferative neoplasms.

Read more

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes ...

Stockholm, June 14, 2013 Dr Valentin Goede will present promising outcomes for elderly CLL patients at the 18th Congress of the European Hematology Association in Stockholm.

Read more

Press release: 18th Congress of the European Hematology Association in Stockholm...

Since 2010 the European Hematology Association (EHA) and the Wallace H Coulter Foundation (WHCF) have been in a close partnership, in which EHA was the beneficiary of generous donations for its projects. The support of the WHCF has been the prime mover for the setup of the EHA-ASH Translational Research Training in Hematology (TRTH) program and an important contributor towards the vast expansion of EHA’s outreach program. Both programs have had a major impact on the Association’s array of activities and global network.

The importance of the achievements of Wallace Coulter, the inventor of the Coulter Counter - the most valuable tool in the hematology laboratory, as a person and his organization cannot be underestimated for the hematological community as well as for EHA due to the Foundation’s support. EHA is glad to be able to pay tribute and commemorate the 100th birthday of Wallace Coulter.

Read more

Press release: Work of 2013 Nobel Prize in Physiology or Medicine winners to be ...

This year the Scientific Working Group Session on hematopoietic stem cells will focus on the recent advance in the field of “Induced Pluripotent Stem Cells (IPSC)”.

Read more

Press Release: News on Red Cells and Iron presented at the 18th Congress of the ...

Iron deficiency anaemia continues to me the most common disease in the world, affecting millions of people, mostly women. Failure to find an underlying cause of iron deficiency and failure to respond to iron replacement often points to a completely different mechanism of anaemia which is usually congenital and surprisingly can lead to excess accumulation of iron and ill health.

Read more

Press release: Breaking news on lymph node cancer and plasma cell cancer reporte...

Breaking news on Lymphoma (lymph node cancer) and Myeloma (plasma cell cancer) reported at meetings of Scientific Working Groups during the European Hematology Congress in Stockholm, June 13-16, 2013  

Read more

EU commissioner Tonio Borg: 'we will continue to improve the life of people suff...

 

Read more